Equillium

$4.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (+0.20%) Today
+$0.05 (+1.02%) As of 5:12 AM EST after-hours

Why Robinhood?

You can buy or sell Equillium and other stocks, options, and ETFs commission-free!

About EQ

Equillium, Inc. Common Stock, also called Equillium, is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA. The listed name for EQ is Equillium, Inc. Common Stock.

CEO
Bruce D. Steel
Employees
16
Headquarters
La Jolla, California
Founded
2017
Market Cap
121.66M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.04M
High Today
$5.03
Low Today
$4.83
Open Price
$4.88
Volume
438.62K
52 Week High
$27.05
52 Week Low
$2.20

Collections

EQ News

MarketWatchNov 25

Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatment

Shares of Equillium Inc. EQ, -3.04% tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 tria

EQ Earnings

-$0.45
-$0.30
-$0.15
-$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 25, After Hours

You May Also Like